Antisense Therapeutics Limited (AU:PER) has released an update.
Percheron Therapeutics Limited has announced the World Health Organization’s selection of ‘avicursen’ as the proposed international nonproprietary name for its drug candidate ATL1102, aimed at treating rare diseases. The definitive confirmation of the INN is anticipated in May 2025, after which the company plans to adopt the new name. This milestone marks a significant step toward preparing ATL1102 for potential marketing authorization.
For further insights into AU:PER stock, check out TipRanks’ Stock Analysis page.
